Published in Clin Chem Lab Med on January 01, 2006
A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis (2011) 1.05
Genome-wide association study of determinants of anti-cyclic citrullinated peptide antibody titer in adults with rheumatoid arthritis. Mol Med (2009) 0.88
Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity. MAbs (2015) 0.84
Predictive value of autoantibody testing for validating self-reported diagnoses of rheumatoid arthritis in the Women's Health Initiative. Am J Epidemiol (2013) 0.83
Anti-cyclic citrullinated peptide antibodies--activity markers in rheumatoid arthritis. J Med Life (2010) 0.75
Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol (2006) 1.17
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther (2011) 1.09
High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther (2009) 1.05
Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res (2001) 1.02
Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum (2007) 0.99
[Structural change in the DGRh]. Z Rheumatol (2004) 0.96
Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum (2005) 0.90
Development of a CENP-A/CENP-B-specific immune response in a patient with systemic sclerosis. Arthritis Rheum (2002) 0.82
Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. J Rheumatol (2015) 0.80
[Study of antibodies (ENA, ANA)]. Dtsch Med Wochenschr (2002) 0.75
[The clinical spectrum of dermatomyositis]. J Dtsch Dermatol Ges (2005) 0.75
[Comments by the German Society of Rheumatology (DGRh) to report on the plan for Biologicals in the second-line therapy of rheumatoid arthritis]. Z Rheumatol (2011) 0.75